The role of polyamines in glucagon-like peptide-2 prevention of TPN-induced gut hypoplasia.
Total parenteral nutrition (TPN) of rats has been demonstrated to produce hypoplasia of gut mucosa, and to be associated with reduced immune response and elevated translocation of bacteria from gut to mesenteric lymph nodes, spleen and liver. Treatment of rats being maintained on TPN with the proglucagon fragment, glucagon-like peptide-2 (GLP-2), has been shown to totally prevent small intestine mucosal hypoplasia. In the present study, we found that depletion of polyamines with alpha-difluromethylornithine (DFMO) significantly reduced the efficacy of GLP-2 in preserving gut mucosa in rats maintained on TPN for 8 days. Co-infusion of GLP-2 with TPN prevented loss of protein and mucosa in duodenum, jejunum and ileum, but not in colon. Addition of DFMO to the infusate prevented the protective effects of GLP-2 in the duodenum and jejunum. In the jejunum, putrescine and spermidine were reduced in DFMO-treated rats, while the ileum exhibited reductions of these polyamines in rats infused with TPN or TPN plus GLP-2. DFMO infusion further reduced these polyamines in the ileum, while levels of spermine were increased. Concentrations of ornithine decarboxylase were elevated in jejunum of rats infused with TPN or TPN plus GLP-2, but were reduced significantly in DFMO-treated rats. These results suggest that normal levels of polyamines are necessary for the expression of GLP-2-induced hyperplasia. Differential effects of GLP-2 and DFMO across gut segments may relate to regional differences in proliferative and anti-apoptotic effects of the treatments.
Chance
William T
WT
Medical Research Service, VA Medical Center, Cincinnati, OH, USA. William.Chance@UC.Edu
Sheriff
Sulaiman
S
Dayal
Ramesh
R
Friend
Lou Ann
LA
Thomas
Ingrid
I
Balasubramaniam
Ambikaipakan
A
D000821:Animal Feed; D000818:Animals; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000494:pharmacology*; D007420:Intestine, Large / Q000002:abnormalities* / Q000033:anatomy & histology / Q000187:drug effects*; D007421:Intestine, Small / Q000002:abnormalities* / Q000033:anatomy & histology / Q000187:drug effects*; D008297:Male; D009929:Organ Size; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D011073:Polyamines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344
D053767:Glucagon-Like Peptide 2; D011073:Polyamines; D004763:Glucagon-Like Peptides